Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CPHI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CPHI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

China Pharma Holdings Inc

CPHI
Current price
1.85 USD +0.04 USD (+2.21%)
Last closed 1.70 USD
ISIN US16941T1043
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NYSE
Capitalization 5 904 220 USD
Yield for 12 month +618.45 %
1Y
3Y
5Y
10Y
15Y
CPHI
21.11.2021 - 28.11.2021

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China. Address: No. 17, Jinpan Road, Haikou, China, 570216

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.00 USD

P/E Ratio

Dividend Yield

Financials CPHI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CPHI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+4 528 929 USD

Last Year

+7 011 299 USD

Current Quarter

+1 136 287 000 000 USD

Last Quarter

+1 133 995 USD

Current Year

-1 985 648 USD

Last Year

-281 085 USD

Current Quarter

-136 061 000 000 USD

Last Quarter

-160 589 USD
EBITDA -2 217 851 USD
Operating Margin TTM -66.76 %
Price to Earnings
Return On Assets TTM -18.22 %
PEG Ratio
Return On Equity TTM -59.84 %
Wall Street Target Price 3.00 USD
Revenue TTM 4 295 377 USD
Book Value 2.14 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -17.10 %
Dividend Yield
Gross Profit TTM -1 831 685 USD
Earnings per share -2.22 USD
Diluted Eps TTM -2.22 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -106.30 %

Stock Valuation CPHI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.16
Price Sales TTM 1.37
Enterprise Value EBITDA -225.89
Price Book MRQ 0.88

Technical Indicators CPHI

For 52 Weeks

1.20 USD 3.35 USD
50 Day MA 1.86 USD
Shares Short Prior Month 63 443
200 Day MA 2.08 USD
Short Ratio 0.92
Shares Short 49 748
Short Percent 1.69 %